Drug Discovery World
AUGUST 2, 2023
Renaissance Pharma has announced its first development programme focused on Hu14.18, a humanised anti-GD2 monoclonal antibody (mAb), licensed from St Jude Children’s Research Hospital for the treatment of newly diagnosed high-risk neuroblastoma. A novel Phase II trial incorporating Hu14.18 and three-year event-free (EFS) of 73.7%.
Drug Discovery World
SEPTEMBER 3, 2024
The therapy is now approved by both the FDA and China Center for Drug Evaluation (CDE) to enter clinical trials in both countries for advanced solid tumour patients. Diana Spencer, Senior Digital Content Editor, DDW The post FDA clears genetically engineered TIL therapy for solid tumour trials appeared first on Drug Discovery World (DDW).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
DECEMBER 7, 2023
A potential schizophrenia treatment, discovered at Vanderbilt University in Tennessee in the US, has been cleared by the US Food and Drug Administration for use in Phase I clinical trials. The post Potentially game-changing schizophrenia drug enters Phase I trials appeared first on Drug Discovery World (DDW).
Drug Discovery World
NOVEMBER 24, 2023
Project leader, Associate Professor Keith Chappell, said the preliminary clinical trial results were an ‘exciting reward’ for the team’s continued dedication and the community’s widespread support for the project. “We The Clamp2 trial group showed a 2.5-fold fold boost in neutralising ‘titres’ and it was 2.1 in the Novavax group.
Drug Discovery World
JANUARY 16, 2024
The Jenner Institute at the University of Oxford is conducting the study using Bacille Calmette-Guérin (BCG), the current licensed vaccine against TB. The post Clinical trial will test novel inhaled TB vaccine appeared first on Drug Discovery World (DDW).
Drug Discovery World
AUGUST 14, 2023
Sosei Group and Cancer Research UK announced that the first patient has been dosed in a Phase I/IIa clinical trial evaluating Sosei Heptares’ immunotherapy drug HTL0039732. Chief Investigator Dr Bristi Basu, University of Cambridge, and Co-Chief Investigator Dr Debashis Sarker, King’s College London, are leading the trial.
Drug Discovery World
MARCH 13, 2024
Johnson & Johnson has announced the first data from FRONTIER 2, the long-term extension of the Phase IIb FRONTIER 1 clinical trial evaluating JNJ-2113, the first and only investigational targeted oral peptide designed to block the IL-23 receptor. at 16 weeks and 76.2% at 52 weeks). .”
Expert insights. Personalized for you.
246 
Let's personalize your content